Abnormal Spontaneous Regional Brain Activity in Young Patients With Anorexia Nervosa - 23/10/19

Abstract |
Objective |
Functional magnetic resonance imaging (fMRI) studies have repeatedly shown alterations in patients with anorexia nervosa (AN). These alterations might be driven by baseline signal characteristics such as the (fractional) amplitude of low frequency fluctuations (fALFF/ALFF), as well as regional signal consistency (ie, regional homogeneity [ReHo]) within circumscribed brain regions. Previous studies have also demonstrated gray matter (pseudo-) atrophy in underweight individuals with AN. Here we study fALFF/ALFF and ReHo in predominantly adolescent patients with AN, while taking gray matter changes into consideration.
Method |
Resting state fMRI data were acquired from a sample of 148 female volunteers: 74 underweight patients with AN and 74 age-matched female healthy controls (HC).
Results |
Group differences for fALFF and ReHo measures were found in several AN-relevant brain regions, including networks related to cognitive control, habit formation, and the ventral visual stream. Furthermore, the magnitude of correlation between gray matter volume/thickness and fALFF and ReHo were reduced in AN compared to HC.
Conclusion |
Abnormal local resting state characteristics in AN-related brain-networks as well as reduced structure−function relationships may help to explain previously reported task-related and classical resting state neural alterations in underweight AN. Patients with AN may serve as a valuable population for investigating dynamic changes in the relationships between brain structure and function.
Le texte complet de cet article est disponible en PDF.Key words : anorexia nervosa, resting state, regional homogeneity, amplitude of low-frequency fluctuations (ALFF)
Plan
| This work was supported by the Deutsche Forschungsgemeinschaft (EH 367/5-1, EH 367/7-1, and SFB 940) and the Swiss Anorexia Nervosa Foundation. |
|
| The authors would like to express their gratitude to Laura Soltwedel, MD, Benjamin Roschinski, MD, Sabine Clas, Dipl.-med, Juliane Petermann, Dipl.-med, Anne Schulze, Dipl.-med, Stefanie Huber, Dipl.-med, Matthias Beck, Dipl.-med, Pascal Friebel, MSc, Lea Scheuvens, MSc, and Nadja Schutkowski, MSc, all from the Division of Psychological and Social Medicine and Developmental Neuroscience at the Technische Universität Dresden, and Johannes Zwipp, Dr.rer.Medic, from the Eating Disorder Research and Treatment Center at the Department of Child and Adolescent Psychiatry and the University Clinic Dresden, for their assistance with participant recruitment and data collection and thank all participants for their time and cooperation. The authors thank the Centre for Information Services and High Performance Computing (ZIH) at TU Dresden for generous allocations of computer time. |
|
| Disclosure: Dr. Roessner has received payment for consulting and writing activities from Eli Lilly and Co., Novartis, and Shire Pharmaceuticals; lecture honoraria from Eli Lilly and Co., Novartis, Shire Pharmaceuticals, and Medice Pharma; and support for research from Shire and Novartis. He has carried out (and is currently carrying out) clinical trials in cooperation with Novartis, Shire, and Otsuka. Drs. Seidel, King, Boehm, Bernardoni, Biemann, Walter, and Ehrlich, Ms. Borchardt, Mr. Geisler, and Ms. Pauligk report no biomedical financial interests or potential conflicts of interest. |
Vol 58 - N° 11
P. 1104-1114 - novembre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
